Giving the easy access of ctDNA and the results of the trials showing a positive correlation of ctDNA-detected PIK3CA mutations [21,78], US FDA approved the liquid biopsy testing, recommending the possibility to verify the presence of PIK3CA mutations in the tumor tissue when ctDNA testing has resulted negative [33,69]. This evidence concerns the gene PIK3CA and neoplasm.